SCH-50971

SCH-50971 is a histamine H₃ receptor agonist which was under development for the treatment of anxiety disorders, gastrointestinal disorders, and migraine but was never marketed.^[2][3]

SCH-50971

Clinical data
Other names	Sch-50971
Routes of administration	Oral[1]
Drug class	Histamine H3 receptor agonist
ATC code	None
Identifiers
IUPAC name 5-[(3R,4R)-4-methylpyrrolidin-3-yl]-1H-imidazole
PubChem CID	9815232
ChemSpider	7990982
ChEMBL	ChEMBL313127
Chemical and physical data
Formula	C8H13N3
Molar mass	151.213 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H]1CNC[C@@H]1C2=CN=CN2
InChI InChI=1S/C8H13N3/c1-6-2-9-3-7(6)8-4-10-5-11-8/h4-7,9H,2-3H2,1H3,(H,10,11)/t6-,7-/m0/s1 Key:KTEPQLOOQDLKHF-BQBZGAKWSA-N

Pharmacology

The drug acts as a potent, selective, and high-affinity agonist of the histamine H₃ receptor.^[4][5] It has negligible affinity for the histamine H₁ receptor and other assessed receptors.^[4] The drug is also not a histamine H₂ receptor antagonist.^[4] It has greatly improved selectivity compared to the earlier selective histamine H₃ receptor agonist (R)-α-methylhistamine.^[4][5] The drug is orally active and shows anti-allergy effects, antimigraine effects, sedative and hypnotic effects, and hypolocomotion in animals.^[6][7][1] In terms of chemical structure, it is a cyclized pyrrolidine derivative of histamine.^[8][4]

Development

SCH-50971 was under development by Schering-Plough.^[2] It reached the discovery or preclinical research stage of development.^[3] The development of the drug was discontinued by 2001.^[2] SCH-50971 was first described in the scientific literature by 1994.^[9][10]

See also

• BP 2.94
• Cipralisant (GT-2331)
• GT-2203 (VUF-5296)